Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 9:59 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 673–696 of 1,144 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Grippe Clear all

Conditions: Influenza
Interventions: Quadrivalent seasonal influenza vaccine GSK2282512A, Fluarix™ VB, Fluarix™ YB; Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 6 Months to 17 Years
Enrollment: 3,109 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 16
States / cities: Chandler, Arizona • Scottsdale, Arizona • Harrisburg, Arkansas + 13 more

Conditions: Influenza
Interventions: oseltamivir [Tamiflu]; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 1 Year to 12 Years
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 4
States / cities: West Palm Beach, Florida • Pittsburgh, Pennsylvania • Jackson, Tennessee + 1 more

Conditions: Influenza, Human, Pregnancy, Birth Defect
Interventions: Flucelvax Trivalent Influenza Vaccine, Flucelvax Quadrivalent Influenza Vaccine; Biological
Lead sponsor: Seqirus; Industry
Eligibility: Female only
Enrollment: 692 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Wilmington, North Carolina

Conditions: Influenza A
Interventions: VX-787 300 mg, VX-787 600 mg, Oseltamivir 75 mg, Placebo; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 292 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 129
States / cities: Athens, Alabama • Birmingham, Alabama • Gulf Shores, Alabama + 126 more

Conditions: Aspergillosis, Candidemia, C. Difficile
Interventions: Not listed
Lead sponsor: University of Arkansas; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2015
U.S. locations: 1
States / cities: Little Rock, Arkansas

Conditions: Influenza, Influenza -Like Illness, Influenza, Human
Interventions: Recombinant Influenza Vaccine, Standard Dose Quadrivalent Influenza Vaccine; Biological
Lead sponsor: Insight Therapeutics, LLC; Other
Eligibility: 18 Years to 120 Years
Enrollment: 1,989 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: Norfolk, Virginia

Conditions: Influenza
Interventions: Standard IIV4, Recombinant, Cell-culture; Biological
Lead sponsor: Marshfield Clinic Research Foundation; Other
Eligibility: 18 Years to 64 Years
Enrollment: 366 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 1
States / cities: Marshfield, Wisconsin

Conditions: Prematurity of Fetus
Interventions: Oseltamivir; Drug
Lead sponsor: St. Louis Children's Hospital; Other
Eligibility: Up to 6 Months
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Influenza
Interventions: influenza vaccine, reminders letters, raffle prize; Behavioral
Lead sponsor: The Cleveland Clinic; Other
Eligibility: Not listed
Enrollment: 800 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2005
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: No Conditions
Interventions: Health Education, Health Education Training; Behavioral
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 50 Years and older
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Influenza
Interventions: Fluzone®; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 40 Years
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Influenza
Interventions: CR6261 2 mg/kg, CR6261 5 mg/kg, CR6261 15 mg/kg, CR6261 30 mg/kg, CR6261 50 mg/kg, Placebo; Biological
Lead sponsor: Crucell Holland BV; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 64 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Seasonal Influenza
Interventions: mRNA-1030, mRNA-1020, mRNA-1010, Active Comparator; Biological
Lead sponsor: ModernaTX, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 572 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 15
States / cities: Phoenix, Arizona • Coral Gables, Florida • Jupiter, Florida + 12 more

Conditions: Influenza
Interventions: inactivated split-virus influenza vaccine; Biological
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 18 Years to 65 Years
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2002 – 2003
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Healthy Volunteers
Interventions: Bimekizumab; Drug
Lead sponsor: UCB Biopharma S.P.R.L.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 56 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Influenza
Interventions: CD388 Injection, Placebo; Combination Product
Lead sponsor: Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA); Industry
Eligibility: 18 Years to 63 Years
Enrollment: 5,071 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 56
States / cities: Anniston, Alabama • Cullman, Alabama • Tempe, Arizona + 51 more

Conditions: Influenza, SARS-CoV-2
Interventions: mRNA-1083; Biological
Lead sponsor: ModernaTX, Inc.; Industry
Eligibility: 50 Years to 64 Years
Enrollment: 931 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 12
States / cities: Hialeah, Florida • Hollywood, Florida • Miami, Florida + 9 more

Conditions: Influenza, Swine-origin A/H1N1 Influenza
Interventions: Monovalent Subvirion A/H1N1 Influenza vaccine (7.5 µg of HA), Monovalent Subvirion A/H1N1 Influenza vaccine (15 µg of HA), Monovalent Subvirion A/H1N1 Influenza vaccine (30 µg of HA), Normal saline solution (placebo); Biological
Lead sponsor: Sanofi Pasteur, a Sanofi Company; Industry
Eligibility: 18 Years and older
Enrollment: 849 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 15
States / cities: Hoover, Alabama • Chandler, Arizona • Phoenix, Arizona + 12 more

Conditions: Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
Interventions: fludarabine phosphate, melphalan, nonmyeloablative allogeneic hematopoietic stem cell transplantation, intensity-modulated radiation therapy, tomotherapy, total marrow irradiation, total nodal irradiation; Drug · Procedure · Radiation
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 16 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Duarte, California

Conditions: Influenza, COVID-19
Interventions: Influenza and COVID-19 Combination A, Licensed influenza vaccine, COVID-19 Vaccine, Influenza and COVID-19 Combination B, Placebo, Investigational influenza vaccine; Biological
Lead sponsor: BioNTech SE; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 8,795 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 106
States / cities: Athens, Alabama • Birmingham, Alabama • Mobile, Alabama + 76 more

Conditions: Influenza
Interventions: Not listed
Lead sponsor: Quidel Corporation; Industry
Eligibility: Not listed
Enrollment: 2,500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011
U.S. locations: 16
States / cities: Carlsbad, California • Panorama City, California • San Diego, California + 13 more

Conditions: Influenza
Interventions: Intravenous hyperimmune immunoglobulin (Flu-IVIG), Placebo; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 11
States / cities: San Diego, California • Denver, Colorado • Washington D.C., District of Columbia + 8 more

Conditions: Influenza, Human
Interventions: F2C22C/DL001Z, F2B22A/DL001Z, F2B22B/DL001Z, F2B22C/DL001Z, F2B22D/DL001Z, F2B22E/DL001Z, F2F22A/DL001Z, F2F22B/DL001Z, F2F22C/DL001Z, F2F22D/DL001Z, F2F22E/DL001Z, Control 1, F2F23D/DL001Z-NH, F2F23A/DL001Z-NH, F2F23B/DL001Z-NH, Control 2, F2F23C/DL001Z-NH, Control 3, F2F22F/DL001Z; Biological · Combination Product
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 1,275 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 24
States / cities: Hialeah, Florida • Miami, Florida • Chicago, Illinois + 21 more

Conditions: Influenza (Pandemic)
Interventions: Monovalent Avian Influenza VLP (H7N9), Matrix-M1™ adjuvant, Placebo; Biological
Lead sponsor: Novavax; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 610 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 5
States / cities: Walnut Creek, California • Miami, Florida • Meridian, Idaho + 2 more

Search by objective public record fields.

A Study to Evaluate the Safety and Immunogenicity of GSK Biologicals' Seasonal Influenza Vaccine in Children

A Study of Tamiflu (Oseltamivir) for Seasonal Prophylaxis of Influenza in Children.

Flucelvax (TIVc or QIVc) Pregnancy Registry

Study of Acute Uncomplicated Seasonal Influenza A in Adult Subjects

UARK 2009-99 A Non-interventional Observational Study of Infectious Complications in Cancer Patients

Recombinant Influenza Vaccination in U.S. Nursing Homes

Randomized Influenza Vaccine Evaluation of Immune Response

Pharmacokinetics of Oseltamivir in Newborns and Infants

Improving Influenza Vaccination Rates Among Health Care Professionals

Health Management Training to Enhance Influenza Vaccine Immunogenicity

Young Adult Influenza Vaccine Immunogenicity Substudy

Assessment of CR6261, a Monoclonal Antibody Against the Influenza A Virus

A Study of mRNA-1020 and mRNA-1030 Seasonal Influenza Vaccines in Healthy Adults

Influenza Vaccination in Bone Marrow Transplantation

A Study to Evaluate the Antibody Response of Influenza Vaccination Following Concomitant Exposure to Bimekizumab in Healthy Subjects

Study of CD388 for the Prevention of Influenza in Subjects Not at Risk for Influenza Complications

A Clinical Study to Investigate the Safety and Immunogenicity in Relation to Product Attributes of mRNA-1083 (Severe Acute Respiratory Syndrome Coronavirus 2 [SARS-CoV-2] and Influenza Vaccine)

A Study of Different Formulations of an A/H1N1 Pandemic Vaccine in Healthy Adults and the Elderly

Total Marrow and Total Lymph Node Irradiation, Fludarabine, and Melphalan Followed By Donor Stem Cell Transplant in Treating Patients With Advanced Hematological Cancer That Has Not Responded to Treatment

A Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Combined Modified RNA Vaccine Candidate Against COVID-19 and Influenza.

"Quidel Reader Influenza A + B Test 510(k) and CLIA Waiver Field Study"

Anti-Influenza Hyperimmune Intravenous Immunoglobulin Pilot Study (INSIGHT 005: Flu-IVIG Pilot)

A Study to Assess the Safety and Immune Response of a Vaccine Against Influenza in Healthy Younger and Older Adults

A(H7N9) VLP Antigen Dose-Ranging Study With Matrix-M1™ Adjuvant